ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

Robert Yarchoan, KentJ Weinhold, H. Kim Lyerly, Edward Gelmann, RobertM Blum, GeneM Shearer, Hiroaki Mitsuya, JerryM Collins, CharlesE Myers, RaymondW Klecker, PhillipD Markham, DavidT Durack, S. Nusinoff Lehrman, DavidW Barry, Margaret A Fischl, RobertC Gallo, DaniP Bolognesi, Samuel Broder

Research output: Contribution to journalArticle

586 Citations (Scopus)

Abstract

In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). AZT was given intravenously for 2 weeks, then orally for 4 weeks at twice the intravenous dose. AZT was well absorbed from the gut and crossed the bloodbrain barrier. Therapeutic levels were maintained with 5 mg given intravenously or 10 mg given orally every 4 h. Treatment was not limited by side-effects, the commonest of which were headaches and depression of white-cell counts. 15 of the 19 patients had increases in their numbers of circulating helper-inducer T lymphocytes (p<0·001) during therapy, 6 who were anergic at entry showed positive delayed type hypersensitivity skin test reactions during treatment, 2 had clearance of chronic fungal nailbed infections without specific anti-fungal therapy, 6 had other evidence of clinical improvement, and the group as a whole had a weight gain of 2·2 kg. Also, with the highest dose regimen cultures of peripheral blood mononuclear cells for HTLV III became negative.

Original languageEnglish
Pages (from-to)575-580
Number of pages6
JournalThe Lancet
Volume327
Issue number8481
DOIs
StatePublished - Mar 15 1986

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
HIV
Therapeutics
Mycoses
Delayed Hypersensitivity
Helper-Inducer T-Lymphocytes
Skin Tests
Thymidine
Weight Gain
Headache
Blood Cells
Cell Count
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yarchoan, R., Weinhold, K., Lyerly, H. K., Gelmann, E., Blum, R., Shearer, G., ... Broder, S. (1986). ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. The Lancet, 327(8481), 575-580. https://doi.org/10.1016/S0140-6736(86)92808-4

ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. / Yarchoan, Robert; Weinhold, KentJ; Lyerly, H. Kim; Gelmann, Edward; Blum, RobertM; Shearer, GeneM; Mitsuya, Hiroaki; Collins, JerryM; Myers, CharlesE; Klecker, RaymondW; Markham, PhillipD; Durack, DavidT; Lehrman, S. Nusinoff; Barry, DavidW; Fischl, Margaret A; Gallo, RobertC; Bolognesi, DaniP; Broder, Samuel.

In: The Lancet, Vol. 327, No. 8481, 15.03.1986, p. 575-580.

Research output: Contribution to journalArticle

Yarchoan, R, Weinhold, K, Lyerly, HK, Gelmann, E, Blum, R, Shearer, G, Mitsuya, H, Collins, J, Myers, C, Klecker, R, Markham, P, Durack, D, Lehrman, SN, Barry, D, Fischl, MA, Gallo, R, Bolognesi, D & Broder, S 1986, 'ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX', The Lancet, vol. 327, no. 8481, pp. 575-580. https://doi.org/10.1016/S0140-6736(86)92808-4
Yarchoan, Robert ; Weinhold, KentJ ; Lyerly, H. Kim ; Gelmann, Edward ; Blum, RobertM ; Shearer, GeneM ; Mitsuya, Hiroaki ; Collins, JerryM ; Myers, CharlesE ; Klecker, RaymondW ; Markham, PhillipD ; Durack, DavidT ; Lehrman, S. Nusinoff ; Barry, DavidW ; Fischl, Margaret A ; Gallo, RobertC ; Bolognesi, DaniP ; Broder, Samuel. / ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. In: The Lancet. 1986 ; Vol. 327, No. 8481. pp. 575-580.
@article{ee470ccd59db4026bfde44cf331e5d43,
title = "ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX",
abstract = "In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). AZT was given intravenously for 2 weeks, then orally for 4 weeks at twice the intravenous dose. AZT was well absorbed from the gut and crossed the bloodbrain barrier. Therapeutic levels were maintained with 5 mg given intravenously or 10 mg given orally every 4 h. Treatment was not limited by side-effects, the commonest of which were headaches and depression of white-cell counts. 15 of the 19 patients had increases in their numbers of circulating helper-inducer T lymphocytes (p<0·001) during therapy, 6 who were anergic at entry showed positive delayed type hypersensitivity skin test reactions during treatment, 2 had clearance of chronic fungal nailbed infections without specific anti-fungal therapy, 6 had other evidence of clinical improvement, and the group as a whole had a weight gain of 2·2 kg. Also, with the highest dose regimen cultures of peripheral blood mononuclear cells for HTLV III became negative.",
author = "Robert Yarchoan and KentJ Weinhold and Lyerly, {H. Kim} and Edward Gelmann and RobertM Blum and GeneM Shearer and Hiroaki Mitsuya and JerryM Collins and CharlesE Myers and RaymondW Klecker and PhillipD Markham and DavidT Durack and Lehrman, {S. Nusinoff} and DavidW Barry and Fischl, {Margaret A} and RobertC Gallo and DaniP Bolognesi and Samuel Broder",
year = "1986",
month = "3",
day = "15",
doi = "10.1016/S0140-6736(86)92808-4",
language = "English",
volume = "327",
pages = "575--580",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8481",

}

TY - JOUR

T1 - ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

AU - Yarchoan, Robert

AU - Weinhold, KentJ

AU - Lyerly, H. Kim

AU - Gelmann, Edward

AU - Blum, RobertM

AU - Shearer, GeneM

AU - Mitsuya, Hiroaki

AU - Collins, JerryM

AU - Myers, CharlesE

AU - Klecker, RaymondW

AU - Markham, PhillipD

AU - Durack, DavidT

AU - Lehrman, S. Nusinoff

AU - Barry, DavidW

AU - Fischl, Margaret A

AU - Gallo, RobertC

AU - Bolognesi, DaniP

AU - Broder, Samuel

PY - 1986/3/15

Y1 - 1986/3/15

N2 - In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). AZT was given intravenously for 2 weeks, then orally for 4 weeks at twice the intravenous dose. AZT was well absorbed from the gut and crossed the bloodbrain barrier. Therapeutic levels were maintained with 5 mg given intravenously or 10 mg given orally every 4 h. Treatment was not limited by side-effects, the commonest of which were headaches and depression of white-cell counts. 15 of the 19 patients had increases in their numbers of circulating helper-inducer T lymphocytes (p<0·001) during therapy, 6 who were anergic at entry showed positive delayed type hypersensitivity skin test reactions during treatment, 2 had clearance of chronic fungal nailbed infections without specific anti-fungal therapy, 6 had other evidence of clinical improvement, and the group as a whole had a weight gain of 2·2 kg. Also, with the highest dose regimen cultures of peripheral blood mononuclear cells for HTLV III became negative.

AB - In a 6-week clinical trial 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). AZT was given intravenously for 2 weeks, then orally for 4 weeks at twice the intravenous dose. AZT was well absorbed from the gut and crossed the bloodbrain barrier. Therapeutic levels were maintained with 5 mg given intravenously or 10 mg given orally every 4 h. Treatment was not limited by side-effects, the commonest of which were headaches and depression of white-cell counts. 15 of the 19 patients had increases in their numbers of circulating helper-inducer T lymphocytes (p<0·001) during therapy, 6 who were anergic at entry showed positive delayed type hypersensitivity skin test reactions during treatment, 2 had clearance of chronic fungal nailbed infections without specific anti-fungal therapy, 6 had other evidence of clinical improvement, and the group as a whole had a weight gain of 2·2 kg. Also, with the highest dose regimen cultures of peripheral blood mononuclear cells for HTLV III became negative.

UR - http://www.scopus.com/inward/record.url?scp=0022640412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022640412&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(86)92808-4

DO - 10.1016/S0140-6736(86)92808-4

M3 - Article

C2 - 2869302

AN - SCOPUS:0022640412

VL - 327

SP - 575

EP - 580

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8481

ER -